Visão geral da empresa
A commercial-stage medical technology enterprise, RxSight, Inc., specializes in the research, development, and commercialization of light adjustable intraocular lenses (LAL) designed specifically for use in cataract surgery procedures within the United States. The organization operates within the broader Healthcare sector, specifically focusing on the Medical Devices industry, which positions it to benefit from ongoing advancements in ophthalmic care technologies. As of the latest reported data, the company maintains a market capitalization of $300.42M, generating total annual revenue of $134.48M, while employing a workforce of 461 individuals. These valuation and revenue figures indicate that the company holds a mid-cap profile, suggesting a significant operational footprint that is still subject to the volatility often associated with specialized medical device manufacturers seeking market expansion.
Saúde financeira
The company reported a revenue of $134.48M over the trailing twelve months, yet recorded a net income of -$38,944,000 and an EBITDA of -$44,925,000. The substantial disparity between the positive revenue figure and the negative net income highlights a cost structure where operating expenses and taxes significantly erode pre-tax profits, resulting in a loss on a per-dollar-of-sales basis. Cash flow dynamics are further characterized by a free cash flow of -$1,625,250, which indicates that current operational cash generation is insufficient to cover capital expenditures, necessitating reliance on existing cash reserves to fund ongoing activities. The balance sheet reveals a cash position of $228.13M standing in contrast to total debt obligations of $11.04M, creating a robust liquidity buffer despite the negative earnings. This disparity is quantified by a debt-to-equity ratio of 4.00, which suggests a leveraged capital structure where equity forms the primary base for liabilities, yet the high cash level mitigates immediate solvency risks. Liquidity is further evidenced by a current ratio of 10.95, a metric that signals an exceptionally strong ability to meet short-term obligations with current assets, far exceeding standard industry safety thresholds. Finally, the return on equity stands at -14.0% and the return on assets at -9.6%, metrics that collectively reveal that management is currently utilizing shareholder capital to generate losses rather than positive returns, likely due to heavy investment in growth initiatives or restructuring costs.
Avaliação de valorização
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E stands at -15.09, implying that the market prices in a period of anticipated negative earnings or significant turnaround potential. The price-to-book ratio is recorded at 1.09, suggesting that the stock trades at a slight premium over its book value, indicating that investors are willing to pay more than the net asset value per share. Alternative valuation measures include a price-to-sales ratio of 2.23 and an EV/EBITDA of -1.85, figures that suggest the market is pricing the company based on revenue multiple rather than profitability, a common approach for growth-oriented or distressed medical device firms. Regarding price levels, the 52-week high is $17.52 and the 52-week low is $5.90, placing the current trading range within a volatile band that reflects significant recent price discovery activity. The stock exhibits a beta of 1.21, which indicates that the security's price volatility is 21% higher than the broader market benchmark, exposing investors to elevated systemic risk during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at -18.9%, while earnings growth is listed as N/A given the negative net income position. The decline in revenue suggests a contraction in the top line, and the absence of positive earnings growth reinforces the view that the company is currently in a phase where profitability is not being realized alongside revenue changes. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash is theoretically directed toward operations and capital allocation rather than shareholder payouts. Consequently, the company reinvests its limited free cash flow and existing cash reserves into research, development, and manufacturing capabilities to attempt to reverse the negative revenue trend and restore profitability. The overall growth and income profile is defined by a contractionary revenue phase with zero current dividend income, relying entirely on future operational improvements to alter the trajectory of both sales and earnings.